Anika Therapeutics received CE Mark approval for CINGAL® as a medical device to treat knee osteoarthritis (OA) pain. CINGAL joins Anika’s ORTHOVISC® and MONOVISC® products to treat pain associated with knee OA.
EU launch is slated for coming months through a network of existing and new commercial partnerships.
Health Canada approved CINGAL as a medical device to treat knee OA pain in mid-4Q15; the company is working with its distribution partner to finalize commercial launch in 2Q16 and continues pursuit of FDA regulatory approval, where it is assigned for review by the Center for Drug Evaluation and Research.
Anika Therapeutics received CE Mark approval for CINGAL® as a medical device to treat knee osteoarthritis (OA) pain. CINGAL joins Anika's ORTHOVISC® and MONOVISC® products to treat pain associated with knee OA.
EU launch is slated for coming months through a network of existing and new commercial partnerships.
Health Canada approved CINGAL...
Anika Therapeutics received CE Mark approval for CINGAL® as a medical device to treat knee osteoarthritis (OA) pain. CINGAL joins Anika’s ORTHOVISC® and MONOVISC® products to treat pain associated with knee OA.
EU launch is slated for coming months through a network of existing and new commercial partnerships.
Health Canada approved CINGAL as a medical device to treat knee OA pain in mid-4Q15; the company is working with its distribution partner to finalize commercial launch in 2Q16 and continues pursuit of FDA regulatory approval, where it is assigned for review by the Center for Drug Evaluation and Research.
Copy to clipboard 
